Paradigm Capital has doubled its price target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN) to $9.70, with analyst Scott McAuley maintaining a “Speculative Buy” rating on June 16 after early trial data showed signs the company’s treatment could help the central nervous system repair itself following spinal cord injury. “The […]
With Telus in the mix to take back control of Telus Digital (Telus Digital Stock Quote, Chart, News, Analysts, Financials TSX:TIXT) Scotia Capital analyst Divya Goyal has raised her price target on the latter. As reported by the Globe and Mail, the analyst June 17th maintained her “Sector Perform” rating on Telus Digital while raising […]
Share
Tweet
Share
